Big Day on Deck for Flexion Therapeutics

Flexion Therapeutics (NASDAQ: FLXN) is about to find out if its research efforts will pay off. The U.S. Food and Drug Administration is expected to issue a go/no-go decision on its treatment for osteoarthritis pain of the knee -- Zilretta -- on Oct. 6, and because Zilretta is the company's closest drug to commercialization, the regulators' decision could create a wild swing higher or lower in the company's stock price. Is this company about to become the standard of care or will the FDA give Zilretta a red light?

Is this company about to become the standard of care or will the FDA give Zilretta a red light?

Flexion Therapeutics thinks quarterly Zilretta injections can deliver greater pain relief for osteoarthritis of the knee patients than corticosteroids. Results from one phase 3 trial suggest that's true.

Continue reading

Source: Fool.com